1. Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment 
Michael H. Gold, MD, Mark Lebwohl, MD, Brian S. Biesman, MD, Deanne Mraz Robinson, MD, Lei Luo, MPH, David R. Berk, MD, Gurpreet Ahluwalia, PhD, Nancy Alvandi, PhD 
Journal of the American Academy of Dermatology 
Volume 79, Issue 3, Pages e57-e59 (September 2018)
DOI: /j.jaad
Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

2. Fig 1
Percentage of patients with persistent facial erythema associated with rosacea who had at least a 1-grade composite improvement in CEA and SSA scores from baseline, by study visit and time point. CEA, Clinician Erythema Assessment; SSA, Subject Self-Assessment for rosacea facial redness.
Journal of the American Academy of Dermatology  , e57-e59DOI: ( /j.jaad )
Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

3. Fig 2
Maintenance of response (measured by individual CEA or SSA scores) from hour 3 at the week 4 visit to hour 3 at the week 26 and week 52 visits among patients with persistent facial erythema associated with rosacea. Error bars indicate 95% confidence intervals. CEA, Clinician Erythema Assessment; SSA, Subject Self-Assessment for rosacea facial redness.
Journal of the American Academy of Dermatology  , e57-e59DOI: ( /j.jaad )
Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions